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crucial as the profession continues to work toward establishing a sustainable and 
economically viable role within the dynamic health care system.
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OBJECTIVES: Programs to increase medication adherence are receiving increased 
attention. One incentive for pharmacies to implement such services is the potential 
increase in revenue. The objective was to estimate changes in revenue a community 
pharmacy during the ﬁrst three years after implementing a new medication manage-
ment service (RxSync ServiceSM). METHODS: A Markov economic model was devel-
oped using Excel. Model inputs are average week day/weekend patient volumes, 
current average medication possession ratio (MPR) for chronic medication prescrip-
tions, expected MPR for patients enrolled in the service, goals for enrolling existing 
and new patients into the service, current gross prescription sales, and net proﬁt on 
prescription sales. A three year time frame was used to estimate yearly increases in 
net revenue and monthly patient enrollment and increases in prescription volume. 
Model assumptions are based on data collected from ﬁve pharmacies participating in 
a project with the RxSync ServiceSM. RESULTS: A conservative scenario (70% of 
current target patients in 18 months) resulted in a peak of 414 additional prescriptions/
month at month 30 and increases in net revenue of $2956, $8415, and $9490 for the 
ﬁrst 3 years. An aggressive scenario (12 months) resulted in a peak of 414 additional 
prescriptions/month at month 21 and net revenue increases of $4896, $9364, and 
$9531. Adding a goal of 200 new patients, starting at month 6 and ﬁnishing 12 
months later resulted in a peak of 1,208 new prescriptions/month at month 21 and 
net revenue increases of $8,438, $26,386, $27,806. CONCLUSIONS: The model 
demonstrates that an effective medication adherence management program can 
increase net revenue for a community pharmacy. The increases will be relatively small 
the ﬁrst year of implementation unless a fairly aggressive recruitment strategy is used. 
If economic factors are importing when starting the service, recruitment of new 
patients should be a high priority in the implementation strategy.
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OBJECTIVES: Adverse drug reactions (ADRs) accounts for increased morbidity, mor-
tality, and have a signiﬁcant impact on health care cost. This study was planned to 
assess the incidence and pattern of ADRs among hospitalized patients in nephrology 
department and to estimate the direct cost attributable to ADRs. METHODS: This 
was a prospective surveillance study which included all patients admitted to nephrol-
ogy department of tertiary care hospital within eight months period. Patients were 
monitored from the day of admission till the day of discharge for the occurrence and 
reporting of ADRs through intensive monitoring by investigator (clinical pharmacist) 
and spontaneous reporting by health care professionals. ADRs reported were analysed 
for various parameters. RESULTS: Out of 259 hospitalized patients, 58 patients 
developed 94 ADRs with an overall incidence of 22.39%. In 23 (8.88%) patients, 
ADR was present at the time of hospital admission which accounted for 34 ADRs 
(36.17%). In 3.86% of patients, it was the reason for hospital admission. Drug class 
most commonly implicated in the ADRs was immunosuppressive agents (45.74%). 
Type A reactions (93.61%) were more common among patients. Upon causality 
assessment, majority (53.19%) of the reactions were possible in nature and majority 
(58.51%) was found to be of moderate severity. Total cost attributed to ADRs was 
estimated to be Rs 92,019 and average cost incurred for a patient for managing ADR 
was Rs 1,586.53. CONCLUSIONS: Adverse drug reactions occurred commonly in 
hospitalized patients in nephrology ward. Vigilant monitoring of drugs most com-
monly implicated in ADRs in nephrology ward like immunosuppressive agents is of 
utmost importance to avoid extra cost incurred.
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OBJECTIVES: The federal government provided approximately $29 million from 
2003–2007 to help states establish and maintain prescription drug monitoring pro-
grams (PDMPs) aimed at reducing diversion and abuse of pharmaceuticals. The 
objective of this study is to compare aggregated prescription drug-related mortality 
rates in states with active PDMPs compared to states with inactive PDMPs. 
METHODS: Data on ten states with prescription drug-related mortality rates are 
available from the Drug Abuse Warning Network (DAWN). As of 2007, 6 states had 
active PDMPs: Maine, Massachusetts, New Mexico, Oklahoma, Utah and Virginia. 
Whereas four states had inactive PDMPs: Maryland, New Hampshire, Oregon and 
Vermont. Independent samples t-test was used to determine signiﬁcance (p = 0.10) in 
mean mortality rates between active and inactive PDMPs. RESULTS: Among the 10 
states, 4454 drug-related deaths were reported in 2007. States with active PDMPs 
received a mean of $908,756 compared to $287,056 for states with inactive PDMPs. 
Among states with active PDMPs, New Mexico had the highest drug-related mortality 
rate (21.0%) and among states with inactive PDMPs, Maryland had the highest 
mortality rate (14.6%). A t-test showed no signiﬁcant difference (p = 0.37) in mean 
± SD drug-related death rate per 100,000 people associated with active PDMPs (14.2 
± 5.4) compared to states with inactive PDMPs (11.9 ± 2.2). CONCLUSIONS: Drug-
related mortality rates were lower in states with inactive programs, when compared 
to states with active PDMPs. This result may be representative of political pressure to 
enact programs in states with higher mortality rates. Although the sample size repre-
sents 20% of states, results should be viewed with caution. PDMPs are designed to 
decrease diversion and abuse, as well as associated morbidity and mortality; however 
more research is needed to determine their effectiveness and to devise ways to maxi-
mize their utility.
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OBJECTIVES: Evaluate the useffulness of cost per DDD to identify problematic drugs 
in medium- and high-level complexity hospitals from Colombia. METHODS: This 
was a cross-sectional study where drug prescriptions were evaluated in 331 second- 
and third-level complexity hospitals from 27 Colombian departments during 2006–
2007. RESULTS: A total of 38,863 prescriptions for 3663 patients were analyzed; 
54.7% of them patients afﬁliated to contributory health care system. The medication 
consumption was of 8, 39 daily deﬁned doses (DDD)/1000 patients. Filgastrim and 
Interferon represent almost 48% of DDDs of DU90%. The overall cost per DDD was 
US$3.9, being this cost lower in drugs of DU90% than drug out of this list (US$1.79 
vs.US$10.24, p = 0.03). Also the cost per DDD was higher in patients afﬁliated to 
contributory health care system than patients afﬁliated to public health care system 
(US$ 3.01 vs. US$2.09, p = 0.03). The antineoplastic and immunomodulating agents 
(Code L, ATC Classiﬁcation System), and drugs of musculoskeletal system (Code M, 
ATC Classiﬁcation System) were the drugs with higher cost per DDD (US$ 1686 and 
US$8.9, respectively). CONCLUSIONS: In this population, antineoplastic and immu-
nomodulating agents have cost per DDD that were 100 times higher than other drugs, 
also the estimation of cost per DDD allows identifying problematic drugs in this 
population such as Filgastrim and Interferon which prescriptions must be check care-
fully. Were evident differences of drug’s cost by type of health care system regardless 
that do not exist differences of drugs coverage in the Colombian health system by 
afﬁliation. The cost per DDD and DU 90% are useful indicators to identify problem-
atic drugs in developing countries.
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OBJECTIVES: To calculate the incidence of medication errors (MEs), examine types 
and causes of MEs, and estimate the excess hospital costs attributable to MEs during 
hospitalization. METHODS: The study population included patients who were hos-
pitalized in the medical/surgical units of two hospitals (176-bed community and 
417-bed academic hospitals) from January 2005-December 2006. ME data was col-
lected from hospital-speciﬁc voluntary reports for patients who experienced MEs. 
Hospital costs data was obtained from hospitals’ accounting department and were 
estimated from the payers’ point of view. The excess hospital costs if MEs were 
prevented in patients with MEs were estimated using a recycled prediction method. A 
generalized linear model with gamma distribution and log link function was used to 
derive coefﬁcients of the study variables from all patients. Among the patients with 
ME, the mean cost was predicted using the coefﬁcients derived from all patients, with 
the assumption that patients without MEs. All costs were converted to 2008 US 
dollars. RESULTS: A total of 470 MEs out of 57,554 patients were identiﬁed. The 
overall rate for MEs was 0.8 errors per 100 admissions and 1.7 errors per 1000 
patient-hospitalized days (harmful MEs = 0.4 and non-harmful MEs = 1.3). MEs 
occurred most frequently in the stage of administration(35.7%), followed by transcrip-
tion(25.7%), dispensing(18.5%), and ordering(15.5%). The most common types of 
MEs were wrong time (19.8%), wrong medication (18.1%), and wrong dose (17.0%). 
About 45% of MEs involved antibiotics, opiates, insulin, and electrolytes and ﬂuid. 
If patients who experienced MEs during hospitalization were not to have these MEs, 
their hospital costs would be reduced by $6,973 (95%CI US$6,138–7,808). CON-
CLUSIONS: This study demonstrated the importance of reducing medication errors 
because of its substantial economic burden to our society. Additional studies are 
needed to assess the cost effectiveness of various strategies in reducing MEs.
